Warning: Declaration of Cmdiscwelc_Walker_PostDropdown::walk($elements, $max_depth) should be compatible with Walker::walk($elements, $max_depth, ...$args) in /home/myesopha/public_html/wp-content/plugins/cm-disclaimer-and-welcome/shared/functions.php on line 478
2016 – c2cyroballoon.com

Yearly Archives: 2016

/2016

C2 Therapeutics Announces Initiation of Coldplay III Trial Validating The C2 CryoBalloon™ Focal Ablation System for Primary Treatment of Barrett’s Esophagus

2018-05-30T19:48:05+00:00

REDWOOD CITY, Calif. – June 7, 2016 – C2 Therapeutics today announced the initiation of its Coldplay III trial with treatment of the first patient at University Hospitals in northeast Ohio. The patient was treated with the C2 CryoBalloon™ Focal Ablation System by John Dumot, D.O., Director, Digestive Health Institute, University Hospitals, commencing the clinical trial to validate the efficacy and safety of the system in patients with Barrett’s esophagus.

Click here to see full release.

C2 Therapeutics Announces Initiation of Coldplay III Trial Validating The C2 CryoBalloon™ Focal Ablation System for Primary Treatment of Barrett’s Esophagus 2018-05-30T19:48:05+00:00

C2 Therapeutics Announces Data from Four Studies Reinforcing the Safety and Efficacy of its C2 CryoBalloon™ Focal Ablation System

2018-05-30T19:48:05+00:00

REDWOOD CITY, Calif. – May 24, 2016 – C2 Therapeutics, a privately-held medical device company founded to improve methods of eradicating unwanted tissue in endoscopic applications, today announced new data from four separate clinical studies designed to assess the safety and efficacy of its C2 CryoBalloon™ Focal Ablation System (CbFAS). The data, which support the safety and efficacy of the company’s CbFAS, were presented at Digestive Disease Week (DDW) 2016, which is taking place May 21 – 24 in San Diego.

Click here to see full release.

C2 Therapeutics Announces Data from Four Studies Reinforcing the Safety and Efficacy of its C2 CryoBalloon™ Focal Ablation System 2018-05-30T19:48:05+00:00